The Pro Medicus Limited (ASX: PME) share price has been a strong performer on Thursday.
In morning trade the leading health imaging company’s shares are up 5% to $32.75.
Why is the Pro Medicus share price racing higher?
Investors have been buying the company’s shares this morning following the release of an announcement.
According to the release, Pro Medicus has signed a five-year contract with MedStar Health worth a total of A$18 million.
MedStar Health is the largest health system in the Maryland and Washington, D.C. metropolitan region, comprising 10 hospitals.
The contract is based on a transactional licensing model and will see Pro Medicus’ complete enterprise imaging solution implemented across all of MedStar’s radiology and subspecialty imaging departments. This includes the MedStar Georgetown University Hospital.
Management believes this implementation is notable as it will provide MedStar with a fully cloud deployed environment on the Google Cloud Platform (GCP), leveraging its Visage platform’s native, cloud-engineered enterprise imaging technology.
Planning for the rollout is to commence in the second quarter of FY 2021, with the first sites scheduled to go-live in the third quarter.
A shift in thinking.
Pro Medicus CEO, Dr Sam Hupert, appeared to be very pleased with the agreement and what it could signify for the future.
He commented: “MedStar went through an extensive evaluation process including a pilot that not only benchmarked Visage 7 compared to on-premise systems from other vendors, it served to verify the speed of Visage 7 in the public-cloud.”
“Unlike systems from other vendors, Visage has been developed from the ground up for cloud deployment. Traditionally, our clients have deployed Visage in their own “private-cloud” where all images are sent to a single, central server and streamed on demand from there. This deal signifies a shift in the way U.S. healthcare providers are now starting to think about public-cloud platforms,” he added.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- These are 8 of the best performing ASX healthcare shares of 2020 so far
- ASX 200 Weekly Wrap: ASX 200 on track for a top month
- These were the worst performing ASX 200 shares last week
- Pro Medicus (ASX:PME) share price tumbles 4% after AGM
- ASX 200 events this week that could move the market
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Here’s why the Pro Medicus (ASX:PME) share price is storming 5% higher appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3oX4MhE
Leave a Reply